Article Figures & Data
Figures
- FIGURE 1.
SUVmax of 68Ga-PSMA-11 and 68Ga-RM2 images for all analyzed normal tissues.
- FIGURE 2.
Maximum-intensity-projection 68Ga-RM2 and 68Ga-PSMA-11 images of the 7 enrolled patients.
- FIGURE 3.
83-y-old man with history of Gleason 5 + 4 prostate cancer treated with radiation therapy and androgen blockade, who presented with PSA level of 18.7 ng/mL and noncontributory findings on conventional imaging. Maximum-intensity-projection 68Ga-RM2 and 68Ga-PSMA-11 images, as well as axial PET images, show subcentimeter focal uptake corresponding to lymph nodes on MRI and CT, respectively.
- FIGURE 4.
67-y-old man with history of Gleason 3 + 3 prostate cancer treated with radiation therapy and androgen blockade, who presented with PSA level of 6.7 ng/mL and noncontributory findings on conventional imaging. 68Ga-RM2 images are negative for uptake, whereas maximum-intensity-projection 68Ga-PSMA-11 images, as well as axial PET images, show subcentimeter focal uptake corresponding to pelvic lymph node and right seminal vesicle on CT. These were biopsy-proven to represent metastatic disease.
Tables
Patient no. Age (y) Initial cancer stage Gleason score PSA (ng/mL) Treatment 68Ga-PSMA-11 68Ga-RM2 1 83 II 5 + 4 16.2 HT + IMRT Retroperitoneal LNs Retroperitoneal LNs 2 69 II 3 + 4 6.0 Prostatectomy Retroperitoneal LNs Retroperitoneal LNs 3 75 IV 4 + 5 36.5 Prostatectomy Retroperitoneal LNs, pelvic LN Retroperitoneal LNs, pelvic LN 4 67 III 3 + 3 6.7 Brachytherapy + HT Vas deferens, pelvic LN Negative 5 72 III 4 + 3 3.5 RT Supraclavicular LN Supraclavicular LN 6 81 I 3 + 4 7.4 Prostatectomy Pelvic LNs, seminal vesicle Pelvic LNs, seminal vesicle 7 73 III 4 + 4 18.2 Prostatectomy Mediastinal LNs, retroperitoneal LNs, pelvic LNs, multiple bone lesions Mediastinal LNs, retroperitoneal LNs, pelvic LNs, multiple bone lesions HT = hormone therapy; IMRT = intensity-modulated radiation therapy; LN = lymph node; RT = radiation therapy.
Index 68Ga-PSMA-11 68Ga-RM2 P SUVmax 12.4 ± 7.1 (4.1–43.6) 13.2 ± 8.0 (2.5–33.5) 0.63 SUVmean 7.1 ± 4.0 (2.0–14.4) 7.6 ± 3.8 (2.0–14.4) 0.38 F/N ratio 10.4 ± 9.3 (2.3–42.8) 5.9 ± 4.6 (1.2–18.8) <0.003 F/N ratio 9.2 ± 7.3 (2.4–40.4) 5.2 ± 3.5 (1.6–12.8) <0.02 Data are mean ± SD, followed by range in parentheses.
Patient no. Follow-up results 1 Started bicalutamide and leuprolide, and PSA decreased from 18.7 to 2.53; follow-up MRI showed decreased size and number of retroperitoneal lymph nodes 2 Chose to have no treatment, and PSA increased from 8.6 to 10.9 3 Started bicalutamide and leuprolide, and PSA decreased from 36.4 to 2.2 4 Started no treatment yet, and PSA increased from 6.7 to 12.1; on biopsy, 12 prostate cores were negative and right vas deferens showed metastatic adenocarcinoma (Gleason 4 + 3; 15% of core) 5 Started no treatment yet, and PSA increased from 8.53 to 10.2 6 Started bicalutamide, and PSA decreased from 7.36 to 0.38 7 Started bicalutamide, and PSA decreased from 18.2 to 2.5
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Utility of 64Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68Ga-PSMA-11 PET/CT
- Prospective Comparison of 68Ga-NeoB and 68Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer
- A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer
- A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High-Intensity Focused Ultrasound Therapy
- Comparison of 68Ga-PSMA-617 PET/CT and 68Ga-RM2 PET/CT in Patients with Localized Prostate Cancer Who Are Candidates for Radical Prostatectomy: A Prospective, Single-Arm, Single-Center, Phase II Study
- Correlation of 68Ga-RM2 PET with Postsurgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer
- GRPr Antagonist 68Ga-SB3 PET/CT Imaging of Primary Prostate Cancer in Therapy-Naive Patients
- PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer
- PET Imaging Quantifying 68Ga-PSMA-11 Uptake in Metastatic Colorectal Cancer
- Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-glutamate (18F-FSPG) for PET/CT Imaging in Patients with Newly Diagnosed and Recurrent Prostate Cancer
- Development of Improved Tumor-Residualizing, GRPR-Targeted Agents: Preclinical Comparison of an Endolysosomal Trapping Approach in Agonistic and Antagonistic Constructs
- Simultaneous transrectal ultrasound and photoacoustic human prostate imaging
- Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone
- New Developments in Peptide Receptor Radionuclide Therapy
- PET Using a GRPR Antagonist 68Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients
- Prospective Evaluation of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging
- Will GRPR Compete with PSMA as a Target in Prostate Cancer?
- Approaches to Multireceptor Targeting: Hybrid Radioligands, Radioligand Cocktails, and Sequential Radioligand Applications
- Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers
- 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology
- Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results
- What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer
- Molecular Imaging and Targeted Radionuclide Therapy of Prostate Cancer
- Bombesin-Targeted PET of Prostate Cancer